Yesterday, President Donald J. Trump signed the Right to Try bill into law. The House approved the bill last week and the Senate passed it last summer.
Site Search
In the aftermath of Hurricane Harvey and Hurricane Irma, the Cystic Fibrosis Foundation has provided the following resources. Our Compass team continues to stand by and offer support of those impacted by these storms.
In the aftermath of Hurricane Harvey, our hearts go out to the many people impacted by the storm and flooding, particularly those in our cystic fibrosis community.
Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
The draft bill, crafted by the Senate Health, Education, Labor, and Pensions (HELP) Committee, aims to bring stability to the health insurance marketplaces.
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
Galapagos and Cystic Fibrosis Foundation Therapeutics Sign €1.3 million* Agreement